Clinical trial · Interventional
RE-irradiation of Diffuse MIdline Glioma paTients
NCT06093165CI-TRIAL-00070667REMITnot yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG). The study will introduce a standard re-irradiation treatment schedule for DMG patients who have progressed following primary treatment.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor, Pediatric | Childhood Brain Neoplasm | ALIAS | 0.90 |
| Diffuse Glioma | Diffuse Glioma | ONTOLOGY_EXACT | 0.98 |
| Diffuse Intrinsic Pontine Glioma | Diffuse Intrinsic Pontine Glioma | ONTOLOGY_EXACT | 0.98 |
| Diffuse Midline Glioma, H3 K27M-Mutant | Diffuse Midline Glioma, H3 K27M-Mutant | ONTOLOGY_EXACT | 0.98 |
| Pontine Tumors | — | UNRESOLVED | — |
| Thalamic Tumor | Thalamic Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Re-irradiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- A
- description
- Primary radiotherapy 54Gy/30 fractions
- interventionNames
- Radiation: Re-irradiation
- type
- OTHER
- label
- B
- description
- Any other dose and fractionation for primary radiotherapy than 54gy/30 fractions.
- interventionNames
- Radiation: Re-irradiation
Primary outcomes (1)
- measure
- To evaluate the safety of re-irradiation (reRT)
- timeFrame
- 4 weeks after end of re-irradiation
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Months
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Diffuse midline glioma diagnosis: verified radiologically or histologically Biopsy is not mandatory for REMIT * Age ≥ 12 months to ≤21 years. * Min. 180 days/6 months have elapsed from the first day of the 1st RT course * 1st course of radiotherapy * Full recovery from all acute and subacute toxicities of 1st RT course * Clinical progression of symptoms and/or radiographic progression * Karnofsky performance status scale or Lansky Play Scale \> 50% The performance status should not take the neurological deficits per se into account. NB: Children and adults with a worsening performance status due to glioma-related motor deficit can be included. * Life expectancy \> 12 weeks after start of reRT * Signed informed consent by patient and/or parents or legal guardian Exclusion Criteria: * Presence of leptomeningeal spread or multifocal disease on MRI at progression * Other co-morbidity that according to the treating physician would impair participation in the study * \>1 course of radiotherapy * Neurofibromatosis type 1 * Inability to complete the medical follow-up (geographic, social, or mental reasons)
References
Publications (1)
- DERIVEDOstergaard DE, Embring A, Sehested A, Magelssen H, Vogelius IR, Kjaersgaard M, Nysom K, Mathiasen R, Lukacova S, Maraldo MV. REMIT: Reirradiation of Diffuse Midline Glioma Patients -A Nordic Society of Paediatric Haematology and Oncology Feasibility Study. Clin Oncol (R Coll Radiol). 2025 Jan;37:103682. doi: 10.1016/j.clon.2024.103682. Epub 2024 Nov 6. PMID 39626445